TD Cowen Downgrades Foghorn Therapeutics to Hold

TD Cowen analyst Yaron Werber has downgraded Foghorn Therapeutics (NASDAQ: FHTX) from a Buy rating to Hold. This change reflects a shift in the firm's outlook on the company's performance.